Please login to the form below

Not currently logged in

S-A and Exelixis forge alliance

Sanofi-aventis(S-A) and biotech firm Exelixis collaborate on novel targeted oncology therapies

Sanofi-aventis(S-A) and Exelixis, a development stage biotech company, have joined forces to develop novel targeted oncology therapies. The two companies have entered into a global license agreement for XL147 and XL765 and an exclusive collaboration for the discovery of inhibitors of phosphoinositide-3 kinase (PI3K) for the management of solid malignancies.

Under the agreement, S-A will have an exclusive worldwide license to XL147, an oral PI3K inhibitor, and XL765, an oral dual inhibitor of PI3K and mTOR (mammalian target of rapamycin), both of which are in phase I clinical trials. The French company will have sole responsibility for all subsequent clinical, regulatory, manufacturing and commercial activities. Exelixis will take part in ongoing and potential future clinical trials.

S-A and Exelixis will combine research efforts to establish several preclinical programmes related to isoform-selective inhibitors of PI3K. Under the exclusive discovery collaboration, S-A will have sole responsibility for all subsequent clinical, regulatory, commercial and manufacturing activities of the products that result from the collaboration.

Under the terms of the agreements, S-A will pay Exelixis an upfront cash payment, as well as development and regulatory milestone payments that could reach over $1bn in aggregate for existing and future programmes. Exelixis will also receive royalties and commercial milestones on sales when products are commercialised. 

28th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...